FDA Panel To Decide Whether New Breast, Prostate Cancer Drugs Are Worth The Risks
[ad_1] Summaries of health policy coverage from major news organizations Wednesday, Apr 29 2026 9:06 AM Full Issue FDA staff have expressed concerns about the use of camizestrant to treat metastatic breast cancer and capivasertib for patients with metastatic hormone-sensitive prostate cancer. The Oncologic Drugs Advisory Committee will vote on these two drug applications Thursday….